Survey of Ophthalmology
Volume 45 , Pages S335-S336 , May 2001

A Rationale for Lowering Intraocular Pressure in Glaucoma

  • Robert N Weinreb, MD

      Affiliations

    • Corresponding Author InformationReprint address: Robert N. Weinreb, MD, Glaucoma Center 0946, 9415 Campus Point Drive, N. Suite 251, La Jolla CA 92093-0946

References 

  1. The Advanced Glaucoma Intervention Study (AGIS) . The relationship between control of intraocular pressure and visual field deterioration. The AGIS Investigators. Am J Ophthalmol. 2000;130:429–440
  2. Asrani S, Zeimer R, Wilensky J, et al.  Large diurnal fluctuations in intraocular pressure are an independent risk factor in patients with glaucoma. J Glaucoma. 2000;9:134–142
  3. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Collaborative Normal-Tension Glaucoma Study group. Am J Ophthalmol 126:487–97, 1998
  4. Liu JH, Kripke DF, Twa MD, et al.  Twenty-four-hour pattern of intraocular pressure in the aging population. Invest Ophthalmol Vis Sci. 1999;40:2912–2917
  5. Liu JH, Kripke DF, Hoffman RE, et al.  Nocturnal elevation of intraocular pressure in young adults. Invest Ophthalmol Vis Sci. 1998;39:2707–2712
  6. Martinez-Bello C, Chauhan BC, Nicolela MT, et al.  Intraocular pressure and progression of glaucomatous visual field loss. Am J Ophthalmol. 2000;129:302–308
  7. Orzalesi N, Rossetti L, Invernizzi T, et al.  Effect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertension. Invest Ophthalmol Vis Sci. 2000;41:2566–2573
  8. Weinreb RN, Levin LA. Is neuroprotection a viable therapy for glaucoma?. Arch Ophthalmol. 1999;117:1540–1544

PII: S0039-6257(01)00236-3

Survey of Ophthalmology
Volume 45 , Pages S335-S336 , May 2001

Article Tools